{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-046197","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.223890+00:00","generated_at":"2026-06-17T01:34:36.789540+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics CEO Osvaldo Flores steps down; Gregory Russotti named interim CEO, Michael Diem appointed CFO","bullets":["Osvaldo Flores stepped down as President, CEO, and Board member effective April 11, 2023; no disagreement with the company.","Board appointed Gregory Russotti (previously CTO) as Interim President and CEO; salary raised to $614,092.50.","Russotti received a one-time option grant of 318,750 shares at $3.16/share, vesting over 4 years.","Michael Diem, previously Chief Business Officer, promoted to CFO; compensation for new role TBD.","Board reduced from 8 to 7 members following Flores' departure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-046197","json":"https://secwatch.observer/filing/0001104659-23-046197.json","markdown":"https://secwatch.observer/filing/0001104659-23-046197.md","text":"https://secwatch.observer/filing/0001104659-23-046197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923046197/0001104659-23-046197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923046197/tm239540d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:34:36.789540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1321a70256","claim":"Gregory Russotti was appointed as Interim President and Chief Executive Officer at Century Therapeutics, Inc..","evidence_excerpt":"On April 11, 2023, the Board appointed Gregory Russotti as Interim President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923046197/0001104659-23-046197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"519498cbe6","claim":"Michael Diem changed role as Chief Financial Officer at Century Therapeutics, Inc..","evidence_excerpt":"On April 11, 2023, the Board promoted Michael Diem to Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923046197/0001104659-23-046197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a42c603320","claim":"Osvaldo Flores departed as President and Chief Executive Officer at Century Therapeutics, Inc..","evidence_excerpt":"Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of Century Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923046197/0001104659-23-046197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}